Our offer
We facilitate access to Baltic pharmaceutical markets for your product portfolio, offering wide range of services:
Market access: Development of pharmaco-economical and HTA files, along with comprehensive support throughout the market access process
Medical affairs: Expertise in medical communication and scientific engagement
Marketing strategies: Creation and execution of tailored marketing strategies to drive product successes
Promotional services: Targeted promotional activities to effectively reach and engage key audiences
Regulatory, Pharmacovigilance and Compliance: Ensuring adherence to all regulatory safety and compliance requirements
Distribution and Supply: Efficient distribution and supply chain management across the whole Baltic region
-
For innovative pharmaceutical products, access to the Baltic pharmaceutical market is often a major issue. This is due to the complexity and differences in the requirements and processes, insufficient drug reimbursement budgets, and a number of competent authorities in all three Baltic countries: National Health Insurance Fund of Lithuania (www.ligoniukasa.lrv.lt), State Agency of Medicines of Latvia (www.zva.gov.lv), National Health Service of Latvia (www.vmnvd.gov.lv), Health Insurance Fund of Estonia (www.tervisekassa.ee), Health Ministries of Lithuania and Latvia, Ministry of Social Affairs in Estonia. These factors combined often cause significant delays in appropriate patients getting access to new pharmacological treatments, as documented by the EFPIA WAIT indicator. Furthermore, in many cases market access is ensured only partly - not in line with the entire approved indication of the product.
The BALTIC PHARMABRIDGE team of professionals will help your brand to achieve commercial success by:
Identifying your product value from the payer’s perspective, developing HTA strategies to maximise market opportunities.
Involving seasoned professionals, members of our team, and three partner companies from each of the three Baltic states with proven know-how and successful track record of positive reimbursement file preparations and submissions. This is highly essential given the complexity of the market access process.
Preparing HTA applications, pharmaco-economical files, adapting the global health economic models (CEA, CUA, cost-minimization), preparing cost-efficiency models, budget impact analysis, submitting to the above-mentioned institutions in all three countries.
Collaborating with associations of healthcare professionals and patients to ensure the necessary exchange of general and medical information and understand the unmet needs. We have a wide, well-established professional network including the leading specialists and organizations in oncology, rare diseases, cardiology, and other fields.
Taking a holistic approach to product launch, providing market landscape mapping and sizing, business intelligence, patient journey mapping, treatment pathway, data driven development.
Supporting you throughout the whole market access process, collaborating with the stakeholders, facilitating negotiations or market entry discussions with the local authorities, dealing with public affairs, advocacy strategy and implementation.
Partnerships
Our experience includes the set-up and development of three successful, reliable and long lasting partnerships with Anpharm (Poland), EGIS (Hungary) and Daiichi-Sankyo (Japan). The total revenue created by these partnerships exceeds 8 Mill EUR per year.
BALTIC PHARMABRIDGE is looking for new collaborations with international pharmaceutical companies which are not directly represented in the Baltic states.
We provide good CARE of your product throughout its lifecycle, by that creating tangible business difference.
The total Baltic pharmaceutical market is worth 2,5 billion EUR, 70% of which account for prescription medicines, mostly covered by state reimbursement budgets.
Over the last 5 years the Baltic pharma market has achieved significant growth of +42% with at CAGR exceeding +7%. The further growth is estimated over 5% annually due to many unmet needs and growing economies.
Despite many good recent developments, still patient’s access for new innovative and effective treatments in all 3 Baltic countries remains poor, as it is documented by WAIT indicator of EFPIA.
Out of 167 new drugs, registered in the Baltic states in recent years, only 31 are actually available for our patients in reality. It is clearly not satisfying for patients, healthcare providers and public health in Lithuania, Latvia and Estonia.
The objective of BALTIC PHARMABRIDGE is to fill this gap. With our extensive local know-how and experience we seek to help international pharmaceutical companies to overcome multiple administrative and organizational hurdles of the three Baltic markets, ensuring that patients in Lithuania, Latvia and Estonia have access to new innovative and effective medicines.
Experience and trust
Our employees and cooperation partners are trusted, reliable professionals with a wide experience in international pharmaceutical companies, lasting >100 years in total and have a very good reputation in the Baltic markets.
We are used to work according to highest business and ethical standards. Highly valuable is the wide international professional experience and guidance of Strategic board members. Recommendations are available upon the request.
“I recommend Janis LEJA as a professional and reliable employee or business partner in Latvia or the Baltic region to any pharmaceutical company or healthcare services provider.”
M. Walle, SERVIER, HR BP
Our team
Janis Leja
CEO, Chief of the Board, Partnerships & Management
MD. 30 years of experience at international pharmaceutical companies, including 16 years as General manager of Servier Latvia. Has developed the team and the business to 4th biggest pharma company in Latvia; successful management experience of international partnerships. Board member of SIFFA, Association of International Research-based Pharmaceuticals manufacturers, an EFPIA member.
Jana Zeltina
Project management
20 years of experience at international companies. Coordination and project management experience with partners from several countries.
Specific services are provided by our Partners – reliable and experienced companies from Lithuania, Latvia and Estonia:
HC solutions OU
Market access in Estonia, Lithuania and Latvia. HTA, Pharmaco-economical models. Regulatory services
Farmanis UAB
Pharmaco-economical file preparation for Lithuania. Reimbursement and price evaluation dossiers
Aeng Curum SIA
Market research. HTA and market access. Pharmaco-economical file preparation. Pharmacoeconomics
Oribalt group
Wholesale, storage and supply to customers in all 3 Baltic states. Pharmaceutical responsibility. Good Pharmacy Distribution Practice (GDP). Marketing services
Powerhouse SIA
Baltic market research. Data driven development. Public affairs and communication
-
At BALTIC PHARMABRIDGE, we believe in the power of knowledge, care, and positive work environment. Driven by a common goal to ensure better access to medicines for patients in the Baltic states, you will have the opportunity to shape the future of healthcare while advancing your own career. We rely on good knowledge and experience of our team members, but even more so—we highly value trust and personal development. Given the dynamic environment, it is essential that not only we keep up with the market, but are one step ahead of it.
This will ensure success of our company, creating value for patients, employees and the public, allowing us to regularly donate a portion of our profits to charity.
We collaborate with leading professional associations of the healthcare and pharmaceutical sector in all three Baltic countries. Our goal is to become members of The Innovative Pharmaceutical Industry Association in Lithuania, IFPA; Association of Research-based Pharmaceutical manufacturers in Latvia, SIFFA and Association of Pharmaceutical Manufacturers in Estonia, APME.
The voice and needs of the patients are highly important. We have discussed the possibilities of cooperation with Latvian Network of Patient Organizations, Heart and Cardiovascular Patients Organization “ParSirdi.lv” (www.parsirdi.lv). It is of utmost importance to expand our cooperation network to include patient organizations in all three Baltic states, in line with new partnerships and specific product profiles.
Mission
To ensure access to innovative medicines for patients and healthcare providers in Latvia, Lithuania and Estonia, improving the public health
Values
Building trust through honesty, transparency and ethical practices in every aspect of our work
Ensuring good care for your product throughout its lifecycle leads to improved patient well-being
Fostering a positive and engaging environment that brings enjoyment and satisfaction to our work
Vision
A stable and trustworthy Baltic company dedicated to benefiting patients and healthcare specialists by offering new treatment opportunities.
Committed to supporting our employees by fostering a positive work environment where they can grow and thrive.
Upholding our Corporate Social responsibility by regularly donating a portion of our profits to charity.
Strategic Board
Hugues Renaut
PharmD. Pharma executive. BA investor supporting healthcare innovations. CEO at Health Care Advisory
Experience of Managing Director at Servier for countries of Europe, China, Canada; Global Deal Committee member; European Market Commitee Vice Chair at EFPIA
Ansis Grasmanis
Independent Director. Association of Corporate Treasurers. Business-minded Finance, Banking, and M&A executive with over 20 years of senior leadership experience in UK, Europe, Ukraine etc.
Janis Leja
MD. Pharma senior management experience in the Baltic States with a track record of 3 successful partnerships with Anpharm (Poland), EGIS (Hungary) and Daiichi-Sankyo (Japan). Board member of SIFFA, EFPIA member.
Baltic states
The Baltic states of Lithuania, Latvia and Estonia are in Northern Europe, on the coast of the Baltic Sea.
Lithuania (capital: Vilnius) is the southernmost of the three, with a rich history as a powerful kingdom in medieval Europe and strong national identity and a growing economy today.
Latvia (capital: Riga) lies in the middle, boasting a vibrant cultural scene, a rich history, particularly its strong folk traditions.
Estonia (capital: Tallinn) is the northernmost of the three, known for its advanced digital society, picturesque medieval architecture, and close ties with Finland.
The 3 Baltic capital cities Vilnius, Riga and Tallinn are cultural and political centers with rich histories. The capital cities are important economical centers of each country, all three together contributing to more than a half of total Baltic’s GDP.
Absolute majority of states institutions are located in the capital cities, that host also main Universities, hospitals and biggest enterprises.
Vilnius
is known for its baroque architecture, particularly in its historic Old Town, which is also a UNESCO world heritage site. The city has a strong artistic and intellectual tradition and is the political and cultural heart of Lithuania.
Riga
is the largest city in the Baltic states and features a stunning mix of medieval and art nouveau architecture. It’s a cultural center with numerous museums, theaters, and a bustling arts scene, reflecting the diverse heritage of Latvia.
Tallinn
is known for its well-preserved medieval old town, a UNESCO world heritage site, and its modern, digital-first society. The city is a hub for technology and innovation, and it combines historic charm with a forward-looking, tech-savvy culture.
The Baltic states share historical experiences, now being members of the European Union and NATO. The total population of Baltic states is 6 million people. This is comparable to the population of Finland or Slovakia.
